# EDGAR Filing Document

**Accession Number:** 0001937653
**File Stem:** 0001193125-25-151279
**Filing Date:** 2025-6
**Character Count:** 13394
**Document Hash:** e5358355319ff7ab60e112c58edec8c0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-151279.hdr.sgml**: 20250627

**ACCESSION NUMBER**: 0001193125-25-151279

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250626

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250627

**DATE AS OF CHANGE**: 20250627

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zymeworks Inc.
- **CENTRAL INDEX KEY:** 0001937653
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 883099146
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41535
- **FILM NUMBER:** 251086496

**BUSINESS ADDRESS:**
- **STREET 1:** 108 PATRIOT DRIVE, SUITE A
- **CITY:** MIDDLETOWN
- **STATE:** DE
- **ZIP:** 19709
- **BUSINESS PHONE:** 302-274-8744

**MAIL ADDRESS:**
- **STREET 1:** 108 PATRIOT DRIVE, SUITE A
- **CITY:** MIDDLETOWN
- **STATE:** DE
- **ZIP:** 19709

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zymeworks Delaware Inc.
- **DATE OF NAME CHANGE:** 20220712

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 26, 2025

## Zymeworks Inc.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41535** | **88-3099146** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **108 Patriot Drive, Suite A**<br> **Middletown, Delaware** | **19709** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

(302) 274-8744

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.00001 per share | ZYME | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement.**  |

---

*Amendment to Pre-Funded Warrants* 

On June 26, 2025, Zymeworks Inc. (the "Company") entered into an amendment (the "Amendment") to the outstanding Pre-Funded Warrants to Purchase Shares of Common Stock (the "Pre-Funded Warrants"), issued on December 28, 2023 to EcoR1 Capital Fund, L.P. ("EcoR1") and EcoR1 Capital Fund Qualified, L.P. (together with EcoR1, the "Purchasers") pursuant to the Securities Purchase Agreement, dated December 23, 2023, by and between the Company and the Purchasers (the "Purchase Agreement"). The Purchasers beneficially own in the aggregate more than 5% of the Company's outstanding shares of common stock, $0.00001 par value per share ("Common Stock"). Oleg Nodelman, the manager of EcoR1 Capital LLC ("EcoR1 Capital") (an affiliate of the Purchasers), and Scott Platshon, a partner at EcoR1 Capital, are members of the Company's board of directors.

The Amendment removed the limitation on exercise contained in Section 12 of the Pre-Funded Warrants, which prohibited the exercise of the Pre-Funded Warrants if, after giving effect or immediately prior to such exercise, a Purchaser, together with its affiliates and any other persons whose beneficial ownership of shares of Common Stock would be aggregated with such Purchaser for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own more than 19.99% of the total number of issued and outstanding shares of Common Stock or voting power of the Company following such exercise.

The foregoing description of the material terms of the Amendment is qualified in its entirety by reference to the Amendment attached hereto as Exhibit 10.1, which is incorporated by reference herein.

---

| | |
|:---|:---|
| **Item 3.02** | **Unregistered Sales of Equity Securities.**  |

---

As previously disclosed in a Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") on December 26, 2023, the Company entered into the Purchase Agreement with the Purchasers, pursuant to which the Purchasers purchased 5,086,521 Pre-Funded Warrants to purchase 5,086,521 shares of Common Stock. The per share purchase price for the Pre-Funded Warrants was $9.8299, for an aggregate purchase price of approximately $50 million.

On June 26, 2025, the Purchasers net exercised the Pre-Funded Warrants in full to acquire 5,086,521 shares of the Company's Common Stock at an exercise price of $0.0001 per share. In connection with the net exercise, on June 27, 2025, the Company issued an aggregate of 5,086,480 shares of Common Stock (the "Pre-Funded Warrant Shares"). Following the issuance of the Pre-Funded Warrant Shares, the total number of shares of the Company's Common Stock outstanding as of June 27, 2025 is 74,844,505.

The issuance of the Pre-Funded Warrant Shares was exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof, as a transaction involving the exchange of securities by the Company with existing holders of the Company's securities where no commissions or other remuneration was paid or given, directly or indirectly, to any party for soliciting such exchange.

------

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Amendment No. 1 to Pre-Funded Warrants to Purchase Shares of Common Stock, dated June 26, 2025 by and among the Company and the Purchasers.](d19414dex101.htm) |
| 104 | Cover Page Interactive Data File (embedded as Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ZYMEWORKS INC.** | **ZYMEWORKS INC.** |
|  | (Registrant) | (Registrant) |
| Date: June 27, 2025 | By: | */s/ Kenneth Galbraith* |
|  | Name: | Kenneth Galbraith |
|  | Title: | Chair, Chief Executive Officer and President |

---

## Exhibit 10.1

**Exhibit 10.1** 

**ZYMEWORKS INC.** 

**AMENDMENT NO. 1 TO PRE-FUNDED WARRANTS** 

**TO PURCHASE COMMON STOCK** 

This Amendment No. 1 to Pre-Funded Warrants to Purchase Common Stock (this "**Amendment**") amends those Pre-Funded Warrants (as defined below) issued under that certain Securities Purchase Agreement, dated as of December 23, 2023 (the "**Purchase Agreement**"), and is made and entered into effective as of June 26, 2025 (the "**Effective Date**"), by and among Zymeworks Inc., a Delaware corporation (the "**Company**"), and the investors identified on the signature pages hereto (the "**Holders**"). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the respective meanings assigned to them in the Purchase Agreement or Pre-Funded Warrants, as applicable.

**<u>RECITALS</u>**

**WHEREAS**, on December 28, 2023, the Company issued pre-funded warrants to purchase common stock, $0.00001 par value per share of the Company (the "**Pre-Funded Warrants**") to the Holders pursuant to the terms of the Purchase Agreement.

**WHEREAS**, the Company and the Holders now desire to amend the terms of the Pre-Funded Warrants as set forth below.

**WHEREAS**, pursuant to Section 16(d) of each of the Pre-Funded Warrants, and subject to the last sentence of Section 6.4 of the Purchase Agreement, any provision of the Pre-Funded Warrants may be amended only if the Company obtains the written consent of the Holder.

**NOW, THEREFORE**, in consideration of these premises and the mutual covenants, terms and conditions set forth herein, all of the parties hereto mutually agree as follows:

**<u>AGREEMENT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Amendment to Pre-Funded Warrants</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Section 12 of the Pre-Funded Warrants is hereby deleted in its
entirety and replaced with the following in lieu thereof:

"12. [REMOVED BY AMENDMENT]"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Paragraph 6 of the Form of Exercise Notice on Schedule 1 of the Pre-Funded Warrants is hereby deleted in its entirety and replaced with the following in lieu thereof:

"(6) [REMOVED BY AMENDMENT]"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Governing Law</u>. This Amendment shall be governed in accordance with Section 16(f) of the Pre-Funded Warrants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. <u>Further Amendments; Full Force and Effect</u>. Wherever necessary, all other terms of the Purchase Agreement and each of the Pre-Funded Warrants are hereby amended to be consistent with the terms of this Amendment. Except as specifically set forth herein, each of the Pre-Funded Warrants and the Purchase Agreement shall remain in full force and effect.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. <u>Counterparts; Facsimile</u>. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and upon such delivery any such signature shall be deemed to have the same effect as if the original signature had been delivered to the other party.

[*Signature Page Follows*]

------

The parties have caused this Amendment No. 1 to Pre-Funded Warrants to Purchase Common Stock to be duly executed and delivered by their proper and duly authorized officers as of the Effective Date.

---

| | |
|:---|:---|
| **COMPANY:** | **COMPANY:** |
| **ZYMEWORKS INC.** | **ZYMEWORKS INC.** |
| By: | /s/ Kenneth Galbraith |
| Name: | Kenneth Galbraith |
| Title: | Chair, Chief Executive Officer and President |

---

*[Signature page for Amendment No. 1 to Pre-Funded Warrants to Purchase Common Stock]* 

------

The parties have caused this Amendment No. 1 to Pre-Funded Warrants to Purchase Common Stock to be duly executed and delivered by their proper and duly authorized officers as of the Effective Date.

---

| | |
|:---|:---|
| **INVESTOR:** | **INVESTOR:** |
| **EcoR1 Capital Fund, L.P.** | **EcoR1 Capital Fund, L.P.** |
| By: EcoR1 Capital, LLC, its General Partner | By: EcoR1 Capital, LLC, its General Partner |
| By: | /s/ Oleg Nodelman |
| Name: | Oleg Nodelman |
| Title: | Manager |
| Number of Shares: 268,059 | Number of Shares: 268,059 |
| (subject to adjustment) | (subject to adjustment) |

---

*[Signature page for Amendment No. 1 to Pre-Funded Warrants to Purchase Common Stock]* 

------

The parties have caused this Amendment No. 1 to Pre-Funded Warrants to Purchase Common Stock to be duly executed and delivered by their proper and duly authorized officers as of the Effective Date.

---

| | |
|:---|:---|
| **INVESTOR:** | **INVESTOR:** |
| **EcoR1 Capital Fund Qualified, L.P.** | **EcoR1 Capital Fund Qualified, L.P.** |
| By: EcoR1 Capital, LLC, its General Partner | By: EcoR1 Capital, LLC, its General Partner |
| By: | /s/ Oleg Nodelman |
| Name: | Oleg Nodelman |
| Title: | Manager |
| Number of Shares: 4,818,462 | Number of Shares: 4,818,462 |
| (subject to adjustment) | (subject to adjustment) |

---

*[Signature page for Amendment No. 1 to Pre-Funded Warrants to Purchase Common Stock]*